Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Orexo AB (publ) ORXOF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • SE • USD

SharesGrow Score
18/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Orexo AB (publ) (ORXOF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.29. It has a SharesGrow Score of 17/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $26M, -33.6%/yr average growth. Net income is $129M (loss), growing at +1.9%/yr. Net profit margin is -499.2% (negative). Gross margin is -213.5% (-297.1 pp trend).

Balance sheet: total debt is $491M against $489M equity (Debt-to-Equity (D/E) ratio 1, moderate). Current ratio is 3.7 (strong liquidity). Debt-to-assets is 37.8%. Total assets: $1.3B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ORXOF SharesGrow Score Overview

30/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ORXOF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
30/100
ORXOF: -33.6%/yr revenue is, +1.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ORXOF: Debt-to-Equity (D/E) ratio 1 (moderate), Current ratio is 3.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ORXOF: Net profit margin is -499.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.08-3.23
Volume1K
Avg Volume (30D)22
Market Cap$80.31M
Beta (1Y)0.96
Share Statistics
EPS (TTM)-3.74
Shares Outstanding$34.63M
IPO Date2013-04-11
Employees110
CEONikolaj Sorensen
Financial Highlights & Ratios
Revenue (TTM)$25.93M
Gross Profit$-55.36M
EBITDA$-285.18M
Net Income$-129.47M
Operating Income$-346.03M
Total Cash$910.11M
Total Debt$490.97M
Net Debt$-419.15M
Total Assets$1.3B
Price / Earnings (P/E)-0.6
Price / Sales (P/S)3.1
Analyst Forecast
Company Info
CountrySE
ExchangeOther OTC
CurrencyUSD
ISINSE0000736415

Price Chart

Track all markets on TradingView
ORXOF
Orexo AB (publ) ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
1.08 52WK RANGE 3.23

People Also View

ELAN
ELAN
Elanco Animal Health Incorporated
$23.23
-3.65%
 CTLT
CTLT
Catalent, Inc.
$63.48
+0.00%
 DNPUF
DNPUF
Sumitomo Pharma Co., Ltd.
$11.11
+0.00%
 HYPMY
HYPMY
Hypera S.A.
$4.67
-0.97%
 INVVY
INVVY
Indivior PLC
$21.85
+0.00%
 GNMLF
GNMLF
Genomma Lab Internacional, S.A.B. de C.V.
$1.08
+0.00%
 ESPR
ESPR
Esperion Therapeutics, Inc.
$2.17
+5.85%
 SIGA
SIGA
SIGA Technologies, Inc.
$4.70
+2.62%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message